Davita Inc vs Star Bulk Carriers Corp — how do they compare? Davita Inc trades at $230.44 (market cap $14.92B), while Star Bulk Carriers Corp trades at $26.46 (market cap $2.96B). The key difference: Davita Inc is far larger — about 5× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 3.88% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | SBLK | |
|---|---|---|
Market Cap | $14.92B | $2.96B |
Sector | Health | Industrials |
52-Week High | $235.71 | $28.21 |
52-Week Low | $103.87 | $16.79 |
Enterprise Value | $27.47B | $3.66B |
Dividend Yield | — | 3.88% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Star Bulk Carriers (SBLK) trades at $26.54, up 0.72% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with Q1 2026 earnings beating expectations at $0.56 EPS versus $0.475 expected, while maintaining a healthy 13.01% net income margin. Recent news highlights robust dry bulk rates supporting potential double-digit dividend yields, with the company's modernizing fleet and opportunistic asset sales strengthening the balance sheet.
SBLK presents a compelling opportunity with strong cash flow generation and shareholder returns, though investors face risks from spot rate volatility and cyclical shipping demand. Wall Street maintains bullish sentiment with 14 buy ratings versus 2 sells, while technical indicators show potential resistance near $27 levels. The company's disciplined capital allocation and fleet renewal strategy provide upside potential if dry bulk markets remain favorable.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →